91Â鶹ÌìÃÀÖ±²¥

Journal Article

1. Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami RS (2024). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia. ()
2. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG (2024). A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. Future Oncol, 1-25. ()
3. Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morn-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Sireesha Asoori, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen DK (2024). Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J, 14(1), 180. ()
4. Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK (2024). Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood. ()
5. Badros AZ, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin T, Voorhees PM (2024). Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. ()
6. Mohyuddin GR, Guadamuz J, Ascha M, Chiu BC, Patel P, Sweiss K, Rohrer R, Sborov DW, Calip GS (2024). Comparison of patients with myeloma receiving zoledronic acid versus denosumab: A nationwide retrospective cohort study. Blood Adv, 8(21), 5539-5541. ()
7. Gambles MT, Li S, Kendell I, Li J, Sborov D, Shami P, Yang J, Kopeek J (2024). Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy. ACS Nano, 18(34), 23341-23353. ()
8. Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD Jr, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G (2024). Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transplant Cell Ther, 30(8), 790.e1-790.e16. ()
9. Zanwar S, Galarza Fortuna GM, Sborov DW (2024). Risk-adapted treatment in multiple myeloma: Does more make it merrier? Br J Haematol. ()
10. Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG (2024). Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J, 14(1), 107. ()
11. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leuk Lymphoma, 65(9), 1-4. ()
12. Hydren JR, Lin D, Sweeney NW, Wu B, Kim N, Patel S, Sborov DW, Berdeja JG, Anderson LD Jr, Huo S, Hurtado Martnez JA, Ahlstrom JM (2024). Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group. Front Health Serv, 4, 1354760. ()
13. Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM (2024). Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J, 14(1), 69. ()
14. Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Orlowski RZ, Shain KH, Cowan AJ, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG (2024). Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. ()
15. Sborov DW, Fortuna GG, Hayden PJ (2024). Sequence not salvage. Br J Haematol, 204(5), 1590-1592. ()
16. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J, 14(1), 20. ()
17. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, DAngelo C, Derman B, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee H, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Snedeker J, Kumar R (2024). Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 22(1D), e240001. ()
18. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, DAngelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J (2023). Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(12), 1281-1301. ()
19. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open, 6(11), e2342195. ()
20. Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M (2023). Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience. Haematologica. ()
21. Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK (2023). Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T-cell therapy. Blood Adv. ()
22. Gambles MT, Sborov D, Shami P, Yang J, Kopeek J (2023). Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors. Macromol Biosci, e2300375. ()
23. Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK (2023). Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. ()
24. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG (2023). Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol, 10(10), e825-e837. ()
25. Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin GR (2023). Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. Eur J Haematol, 111(3), 491-498. ()
26. Trunk AD, Patel SS, Prchal JT, Sborov DW, Zander AR, Lee CJ (2023). Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. Leuk Res Rep, 20, 100388. ()
27. Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S (2023). Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. ()
28. Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA (2023). Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J, 13(1), 117. ()
29. Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, Ahmed N, Hashmi H (2023). Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. ()
30. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 1-4. ()
31. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clin Hematol Int. ()
32. Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jimnez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, Garca-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF (2023). Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med, 29(4), 869-879. ()
33. Griffin R, Hanson HA, Avery BJ, Madsen MJ, Sborov DW, Camp NJ (2023). Deep transcriptome profiling of multiple myeloma using quantitative phenotypes. Cancer Epidemiol Biomarkers Prev. ()
34. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK (2023). Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol, JCO2201365. ()
35. Trunk AD, Patel SS, Prchal JT, Sborov DW, Zander AR, Lee CJ (2023). Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. Leuk Res Rep, 20. ()
36. Paul B, Liedtke M, Khouri J, Rifkin R, Gandhi MD, Kin A, Levy MY, Silbermann R, Cottini F, Sborov DW, Sandhu I, Villarreal L, Murphy M, Gu L, Chen A, Rajakumaraswamy N, Usmani SZ (2023). A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. Future Oncol, 19(1), 7-17. ()
37. Li J, Cho YK, Sborov DW, Phelps MA, Hofmeister CC, Poi MJ (2022). Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant. Cancer Genomics Proteomics, 20(1), 9-17. ()
38. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E, Castillo JJ, Costello C, DAngelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R (2023). Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(1), 67-81. ()
39. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. ()
40. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD Jr, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM (2022). Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. ()
41. Berndt SIVijai JBenavente YCamp NJNieters AWang ZSmedby KEKleinstern GHjalgrim HBesson CSkibola CFMorton LMBrooks-Wilson ARTeras LRBreeze CArias JAdami HOAlbanes DAnderson KCAnsell SMBassig BBecker NBhatti PBirmann BMBoffetta PBracci PMBrennan PBrown EEBurdett LCannon-Albright LAChang ETChiu BCHChung CCClavel JCocco PColditz GConde LConti DVCox DGCurtin KCasabonne DDe Vivo IDiver WRDogan AEdlund CKForetova LFraumeni JFGabbas AGhesquires HGiles GGGlaser SGlenn MGlimelius BGu JHabermann TMHaiman CAHaioun CHofmann JNHolford TRHolly EAHutchinson AIzhar AJackson RDJarrett RFKaaks RKane EKolonel LNKong YKraft PKricker ALake ALan QLawrence CLi DLiebow MLink BKMagnani CMaynadie MMcKay JMelbye MMiligi LMilne RLMolina TJMonnereau AMontalvan RNorth KENovak AJOnel KPurdue MPRand KARiboli ERiby JRoman ESalles GSborov DWSeverson RKShanafelt TDSmith MTSmith ASong KW (2022). Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia, 36(12), 2835-2844. ()
42. Campbell RA, Manne BK, Banerjee M, Middleton EA, Ajanel A, Schwertz H, Denorme F, Stubben C, Montenont E, Saperstein S, Page L, Tolley ND, Lim DL, Brown SM, Grissom CK, Sborov DW, Krishnan A, Rondina MT (2022). IFITM3 regulates fibrinogen endocytosis and platelet reactivity in nonviral sepsis. J Clin Invest, 132(23). ()
43. Sborov DW, Baljevic M, Reeves B, Laubach J, Efebera YA, Rodriguez C, Costa LJ, Chari A, Silbermann R, Holstein SA, Anderson LD, Kaufman JL, Shah N, Pei H, Patel S, Cortoos A, Bartlett JB, Vermeulen J, Lin TS, Voorhees PM, Richardson PG (2022). Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol, 199(3), 355-365. ()
44. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565. ()
45. Sonja I Berndt, Joseph Vijai, Yolanda Benavente, Nicola J Camp, Alexandra Nieters, Zhaoming Wang, Karin E Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, Christine F Skibola, Lindsay M Morton, Angela R Brooks-Wilson, Lauren R Teras, Charles Breeze, Joshua Arias, Hans-Olov Adami, Demetrius Albanes, Kenneth C Anderson, Stephen M Ansell, Bryan Bassig, Nikolaus Becker, Parveen Bhatti, Brenda M Birmann, Paolo Boffetta, Paige M Bracci, Paul Brennan, Elizabeth E Brown, Laurie Burdett, Lisa A Cannon-Albright, Ellen T Chang, Brian C H Chiu, Charles C Chung, Jacqueline Clavel, Pierluigi Cocco, Graham Colditz, Lucia Conde, David V Conti, David G Cox, Karen Curtin, Delphine Casabonne, Immaculata De Vivo, W Ryan Diver, Ahmet Dogan, Christopher K Edlund, Lenka Foretova, Joseph F Fraumeni Jr, Attilio Gabbas, Herv Ghesquires, Graham G Giles, Sally Glaser, Martha Glenn, Bengt Glimelius, Jian Gu, Thomas M Habermann, Christopher A Haiman, Corinne Haioun, Jonathan N Hofmann, Theodore R Holford, Elizabeth A Holly, Amy Hutchinson, Aalin Izhar, Rebecca D Jackson, Ruth F Jarrett, Rudolph Kaaks, Eleanor Kane, Laurence N Kolonel, Yinfei Kong, Peter Kraft, Anne Kricker, Annette Lake, Qing Lan, Charles Lawrence, Dalin Li, Mark Liebow, Brian K Link, Corrado Magnani, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L Milne, Thierry J Molina, Alain Monnereau, Rebecca Montalvan, Kari E North, Anne J Novak, Kenan Onel, Mark P Purdue, Kristin A Rand, Elio Riboli, Jacques Riby, Eve Roman, Gilles Salles, Douglas W Sborov, Richard K Severson, Tait D Shanafelt, Martyn T Smith, Alexandra Smith, Kevin W Song, Lei Song, Melissa C Southey, John J Spinelli, Anthony Staines, Deborah Stephens, Heather J Sutherland, Kaitlyn Tkachuk, Carrie A Thompson, Herv Tilly, Lesley F Tinker, Ruth C Travis, Jenny Turner, Celine M Vachon, Claire M Vajdic, Anke Van Den Berg, David J Van Den Berg, Roel C H Vermeulen, Paolo Vineis, Sophia S Wang, Elisabete Weiderpass, George J Weiner, Stephanie Weinstein, Nicole Wong Doo, Yuanqing Ye, Meredith Yeager, Kai Yu, Anne Zeleniuch-Jacquotte, Yawei Zhang, Tongzhang Zheng, Elad Ziv, Joshua Sampson, Nilanjan Chatterjee, Kenneth Offit, Wendy Cozen, Xifeng Wu, James R Cerhan, Stephen J Chanock, Susan L Slager Nathaniel Rothman (2022). Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Am J Leuk Res, 2022, 1-10.
46. Victoria A VardellDaniel A ErmannSrinivas K TantravahiBenjamin HaalandBrian McCluneAmandeep GodaraGhulam Rehman MohyuddinDouglas W Sborov (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 2022, 1-8.
47. Robert A Campbell1 Bhanu Kanth Manne1 Meenakshi Banerjee1 Elizabeth A Middleton1 Abigail Ajanel2 Hansjorg Schwertz1 Frederik Denorme1 Chris Stubben3 Emilie Montenont1 Samantha Saperstein1 Lauren Page1 Neal D Tolley1 Diana L Lim1 Samuel M Brown4 Colin K Grissom4 Douglas W Sborov5 Anandi Krishnan6 and Matthew T Rondina7 (2022). IFITM3 regulates fibronogen endocytosis and platelet reactivity in non-viral sepsis. J Clin Invest, 2022(1).
48. Tommy Gambles M, Li J, Christopher Radford D, Sborov D, Shami P, Yang J, Kopeek J (2022). Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo. J Control Release, 350, 584-599. ()
49. Ghulam Rehman Mohyuddin Jennifer M Ahlstrom Cindy A Chmielewski Nathan W Sweeney Thomas H Molina Christian S Cheung Emily Watabe Ballard Felicia F Seng Oliver Van Oekelen Amandeep Godara Brian McClune Douglas Sborov (2022). A survey on the patient perspective on cure in multiple myeloma. . Lancet Haematol, 9(10), E716-E719.
50. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719. ()
51. Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR (2022). Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol, 8, e2200119. ()
52. Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Ther Adv Hematol, 13, 20406207221100659. ()
53. Kellen Gil, Saqib Abbasi, Kathan Mehta, Brian McClune, Douglas Sborov, Nausheen Ahmed, Al-Ola Abdallah, Siddhartha Ganguly, Joseph McGuirk, Leyla Shune Ghulam Rehman Mohyuddin (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clin Hematol Int, 4((2022)), 56-59.
54. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clin Hematol Int, 4(1-2), 56-59. ()
55. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 12(4), 74. ()
56. Mohammad Ahsen SoomroJames HoffmanAaron Michael GoodmanDouglas Weston SborovGhulam Rehman Mohyuddin (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.  . Br J Haematol, 197(6), e86-e88.
57. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167, 152-160. ()
58. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol. ()
59. Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ, Streiff MB, Kumar SK, Callander NS (2021). Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. J Natl Compr Canc Netw, 20(1), 91-95. ()
60. Steinbach MJulian KMcClune BSborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Ther Adv Hematol, 13. ()
61. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol. ()
62. Li J, Persaud AK, Johnson JA, Sborov DW, Phelps MA, Hofmeister CC, Poi MJ (2021). A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. Anticancer Res, 42(1), 385-395. ()
63. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK (2022). NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw, 20(1), 8-19. ()
64. Gambles MT, Li J, Wang J, Sborov D, Yang J, Kopeek J (2021). Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells. Molecules, 26(15). ()
65. Sagar Lonial MD, Hans C Lee MD, Ashraf Badros MD, Suzanne Trudel MD, Ajay K Nooka MD, Ajai Chari MD, Al-Ola Abdallah MD, Natalie Callander MD, Douglas Sborov MD, Attaya Suvannasankha MD, Katja Weisel MD, Peter M Voorhees MD, Lynsey Womersley MSc, January Baron MS, Trisha Piontek BSN, Eric Lewis MD, Joanna Opalinska MD, Ira Gupta MD, Adam D Cohen MD (2021). Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. July2021(https://doi.org/10.1002/cncr.33809).
66. Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S (2021). The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol, 96(7), 846-853. ()
67. Waller RG, Klein RJ, Vijai J, McKay JD, Clay-Gilmour A, Wei X, Madsen MJ, Sborov DW, Curtin K, Slager SL, Offit K, Vachon CM, Lipkin SM, Dumontet C, Camp NJ (2020). Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Hum Mol Genet, 30(12), 1142-1153. ()
68. M Tommy Gambles, Jiahui Li, Jiawei Wang, Douglas Sborov, Jiyuan Yang, Jindich Kopeek (2021). Crosslinking of CD38 receptors triggers apoptosis of malignant B cells. Molecules, Applied Chemistry Section, Vol. 26(14).
69. Usmani SZ, Karanes C, Bensinger WI, DSouza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG (2021). Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia, 35, 3526-3533. ()
70. Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, Potter HA, Sborov D, Zaugg BE, Popat R, Degli Esposti S, Byrne J, Opalinska J, Baron J, Piontek T, Gupta I, Dana R, Farooq AV, Colby K, Jakubowiak A (2021). Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J, 11(5), 103. ()
71. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510. ()
72. Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, Phelps MA, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi A (2021). A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemother Pharmacol, 87(5), 599-611. ()
73. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V (2020). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol, 8(4), e299-e304. ()
74. Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin GR (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC Cancer, 21(1), 339. ()
75. Ghose J, Dona A, Murtadha M, Gunes EG, Caserta E, Yoo JY, Russell L, Jaime-Ramirez AC, Barwick BG, Gupta VA, Sanchez JF, Sborov DW, Rosen ST, Krishnan A, Boise LH, Kaur B, Hofmeister CC, Pichiorri F (2021). Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Mol Ther Oncolytics, 20, 519-531. ()
76. Mohyuddin GR, Koehn K, Abdallah AO, Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of Endpoints in Multiple Myeloma Randomized Controlled Trials over the Last Fifteen Years: A Systematic Review. Am J Hematol, 96(6), 690-697. ()
77. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK (2020). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 5(4), 1097-1101. ()
78. Ghose J, Dona A, Murtadha M, Gunes EG, Caserta E, Yoo JY, Russell L, Jaime-Ramirez AC, Barwick BG, Gupta VA, Sanchez JF, Sborov DW, Rosen ST, Krishnan A, Boise LH, Kaur B, Hofmeister CC, Pichiorri F (2021). Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Mol Ther Oncolytics, 20, 519-531. ()
79. Waller RG, Madsen MJ, Gardner J, Sborov DW, Camp NJ (2021). Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees. J Transl Genet Genom, 5(2), 112-123. ()
80. Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F (2020). Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 35(1), 189-200. ()
81. Griffin Waller R, Madsen MJ, Gardner J, Sborov DW, Camp NJ (2021). Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees. 5(2), 112-123. ()
82. Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R (2020). Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(12), 1685-1717. ()
83. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther, 9(4), 889-911. ()
84. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K (2020). Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study (Ophthalmology and Therapy, (2020), 9, 4, (889-911), 10.1007/s40123-020-00280-8). Ophthalmol Ther, 9(4), 913-915. ()
85. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K (2020). Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther, 9(4), 913-915. ()
86. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther, 9(4), 889-911. ()
87. Peter M Voorhees, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Jr, Nitya Nathwani, Nina Shah, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S Lin, Paul G Richardson (2020). GRIFFIN Trial Investigators. (2020). Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 136(8), 936-945. Blood, 136(8), 936-945.
88. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG (2020). Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 136(8), 936-945. ()
89. Domenico Viola, Ada Dona, Enrico Caserta, Estelle Troadec, Francesca Besi, Tinisha McDonald, Lucy Ghoda, Emine Gulsen Gunes, James F Sanchez, Jihane Khalife, Marianna Martella, Chatchada Karanes, Myo Htut, Xiuli Wang, Michael Rosenzweig, Arnab Chowdhury, Douglas Sborov, Rodney R Miles, Paul J Yazaki, Todd Ebner, Craig C Hofmeister, Stephen J Forman, Steven T Rosen, Guido Marcucci, John Shively, Jonathan J Keats, Amrita Krishnan Flavia Pichiorri (2020). Daratumumab Induces Mechanisms of Immune activation through CD38+ NK Cell targeting. Leukemia, 35, 189-200.
90. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortm KM, Rodrguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD (2019). Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol, 21(2), 207-221. ()
91. Sharma N, Chen DT, Zhao Q, Williams NY, Rosko A, Benson DM, Chaudhry M, Bumma N, Khan A, Devarakonda S, Hofmeister CC, Sborov D, Efebera YA (2019). Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biol Blood Marrow Transplant, 26(1), 44-49. ()
92. Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, Phelps MA, Hofmeister CC, Poi MJ (2019). XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. Mol Carcinog, 58(12), 2327-2339. ()
93. Kumar SK1, Callander NS2, Hillengass J3, Liedtke M4, Baljevic M5, Campagnaro E6, Castillo JJ7, Chandler JC8, Cornell RF9, Costello C10, Efebera Y11, Faiman M12, Garfall A13, Godby K14, Holmberg L15, Htut M16, Huff CA17, Kang Y18, Landgren O19, Malek E12, Martin T20, Omel J21, Raje N22, Sborov D23, Singhal S24, Stockerl-Goldstein K25, Tan C26, Weber D27, Johnson-Chilla A28, Keller J28, Kumar R28 (2019). NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw.
94. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R (2019). NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw, 17(10), 1154-1165. ()
95. Poi MJ, Li J, Johnson JA, Cho YK, Sborov DW, Phelps MA, Hofmeister CC (2019). A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Res, 39(1), 67-72. ()
96. Cho YK, Irby DJ, Li J, Sborov DW, Mould DR, Badawi M, Dauki A, Lamprecht M, Rosko AE, Fernandez S, Hade EM, Hofmeister CC, Poi M, Phelps MA (2018). Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. CPT Pharmacometrics Syst Pharmacol, 7(11), 748-758. ()
97. Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC (2017). A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma, 58(10), 2310-2318. ()
98. Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA (2017). Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial. Clin Pharmacol Ther, 102(3), 511-519. ()
99. Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC (2017). Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog, 56(7), 1722-1732. ()
100. Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Phelps MA, Hofmeister CC (2017). Construction of a personalized PK melphalan model in the setting of a randomized cryotherapy trial in multiple myeloma patients undergoing autologous stem cell transplantation. Clin Pharmacol Ther.
101. Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC (2017). Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog.
102. Mezache L, Magro C, Hofmeister C, Pichiorri F, Sborov D, Nuovo GJ (2017). Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions. Appl Immunohistochem Mol Morphol, 25(2), 100-109. ()
103. Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F (2016). Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Mol Cancer Ther, 15(5), 830-41. ()
104. Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F (2015). HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 6(31), 31134-50. ()
105. Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K, Efebera Y, Devine S, Hofmeister CC (2015). Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br J Haematol, 171(1), 74-83. ()
106. Sborov D, Chen JL (2015). Targeted therapy in sarcomas other than GIST tumors. J Surg Oncol, 111(5), 632-40. ()
107. Sborov D, Haverkos B, Harris P (2015). Investigational cancer drugs targeting cell metabolism in clinical development. Expert Opin Investig Drugs, 24(1), 79-94. ()
108. Sborov DW, Haverkos BM, Harris PJ (2015). Investigational cancer drugs targeting cell metabolism in clinical development. Expert Opin Investig Drugs, 24(1), 79-94. ()
109. Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC (2014). A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res, 20(23), 5946-55. ()

Review

1. Zhukovsky S, White J, Chakraborty R, Costa LJ, Van Oekelen O, Sborov DW, Cliff ERS, Mohyuddin GR (2024). Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria. [Review]. Leuk Lymphoma, 1-10. ()
2. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24(1), 15-22. ()
3. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. [Review]. Eur J Cancer, 156, 164-174. ()
4. Sborov DW, Rodgers GM (2013). How I manage patients with acquired haemophilia A. [Review]. Br J Haematol, 161(2), 157-65. ()
5. Sborov DW, Rodgers GM (2012). Acquired hemophilia a: a current review of autoantibody disease. [Review]. Clin Adv Hematol Oncol, 10(1), 19-27. ()

Book Chapter

1. Sborov DW, Rodgers GM (2014). Postoperative Strategies for Resumption of Anticoagulants and Antiplatelet Agents in Neurosurgical Patients. In Handbook of Bleeding and Coagulation for Neurosurgery.

Conference Proceedings

1. Sieverts M, Rabbitt N, Parkinson DY, Sborov DW, Acevedo C (2022). Multi-Tissue Analysis Using Synchrotron Radiation Micro-CT Images. In Sieverts M|Rabbitt N|Parkinson DY|Sborov DW|Acevedo C (Ed.), Proceedings - 2022 IEEE 18th International Conference on e-Science, eScience 2022, 74-83. ()

Commentary

1. Sborov, DW (2022). Sborov DW. A commentary on: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. PracticeUpdate website. Available at:https://www.practiceupdate.com/content/defining-new-reference-intervals-for-serum-free-light-chains-in-individuals-with-chronic-kidney-disease/141995/65/1/1. Accessed October 11, 2022. PracticeUpdate Website.

Editorial

1. Baljevic M, Sborov DW, Kumar SK (2024). Long term responders in frontline multiple myeloma-exception vs expectation of the modern era. Blood Cancer J, 14(1), 115. ()
2. Baljevic M, Sborov DW (2023). Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. ()

Letter

1. Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov D (2024). Performance of newer myeloma staging systems in a contemporary, large patient cohort. [Letter to the editor]. Blood Cancer J, 14(1), 95. ()
2. Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK (2024). Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. [Letter to the editor]. J Hematol Oncol, 17(1), 42. ()
3. Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y (2024). Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. [Letter to the editor]. Blood Cancer J, 14(1), 63. ()
4. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma [Letter to the editor]. Clin Hematol Int, 5(2-3), 170-176. ()
5. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Jullian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials [Letter to the editor]. Leuk Lymphoma. ()
6. Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, Sborov D (2022). Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. [Letter to the editor]. Blood Cancer J, 12(12), 168. ()
7. Zhang Y, Godara A, Pan S, Toskic D, Mann H, Sborov D, Comenzo R, Kansagra A (2022). Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma [Letter to the editor]. Ann Hematol, 101(9), 2119-2121. ()
8. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma [Letter to the editor]. Clin Hematol Int, 4(1-2), 56-59. ()
9. Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin GR (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. [Letter to the editor]. Br J Haematol, 197(6), e86-e88. ()
10. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. [Letter to the editor]. Leukemia, 34(1), 317-321. ()
11. John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, Efebera YA, Rosko AE, Vincent J, Hofmeister CC (2018). Most multiple myeloma patients have low testosterone. [Letter to the editor]. Leuk Lymphoma, 60(3), 836-838. ()
12. Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC (2017). G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 58(12), 2947-2951. ()

Abstract

1. Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S Callander, Huan Cheng, Sheel Patel, Rocco J Crescenzo, Amit Agarwal and Binod Dhakal (2023). Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14) : Safety, Efficacy, and Determination of Recommended Phase 2 Dose. ASH- San Diego, CA. [Abstract].
2. Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kunnathu Kumar, S Vincent Rajkumar, Rafael Fonseca, Nadine Abdallah, Greg Calipan, Xiaoyan Wan, Christina Parrinello and Doug Sborov (2023). Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States. ASH- San Diego, CA. [Abstract].
3. Jenny S Guadamuz Rebecca Rohrer Ghulam Rehman Mohyuddin Brian C-H Chiu Pritesh R Patel Karen Sweiss Erlene Seymour Douglas Sborov Gregory S Calip (2022). Abstract 3669: Racial/ethnic disparities in treatment with bone-modifying agents among newly diagnosed multiple myeloma patients.  [Abstract]. 82(12 (Supplement)), 3669.
4. Rafael Fonseca, Junya Kuroda, Tadao Ishida, Rakesh Popat, Jeffrey SY Huang, Anne Yver, Erik Vandendries, Mohamed Elmeliegy, Wei Dong Ma, Douglas W Sborov (2022). MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma. [Abstract]. 40(no. 16 (supplemental)), TPS8068-TPS8068.
5. Cesar Rodriguez, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Ajai Chari, Rebecca Wang Silbermann, Luciano J Costa, Larry D Anderson Jr, Nitya Nathwani, Nina Shah, Naresh Bumma, Andrzej J Jakubowiak, Robert Z Orlowski, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Paul G Richardson, Peter M Voorhees (2022). Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A Post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN. [Abstract]. 40(no. 16 (supplemental)), 8011-8011.
6. Doris K Hansen, Surbhi Sidana, Lauren Peres, Leyla Shune, Douglas W Sborov, Hamza Hashmi, Mehmet H Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher J Ferreri, Aimaz Afrough, Ankit J Kansagra, Peter M Voorhees, Melissa Alsina, Joseph McGuirk, Frederick L Locke, Krina K Patel (2022). Idecabragene vicleucel (ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. [Abstract]. 40(no. 16 (supplemental)), 8042-8042.
7. SaurabhChhabra1Natalie SCallander2Luciano JCosta3Jonathan LKaufman4Jacob PLaubach5Douglas WSborov6BrandiReeves7CesarRodriguez8AjaiChari9Rebecca WSilbermann10Larry DAndersonJr11NityaNathwani12NinaShah13NareshBumma14Sarah AHolstein15CaitlinCostello16AndrzejJakubowiak17Tanya MWildes18Robert ZOrlowski19Kenneth HShain20Andrew JCowan21BhagirathbhaiDholaria22HuilingPei23AnneloreCortoos24SharmilaPatel24J BlakeBartlett25JessicaVermeulen26Thomas SLin24Paul GRichardson27Peter MVoorhees28 (2021). Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant=Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. [Abstract]. 138(Supplement 1), 2852.
8. Zachary DCrees1Keith EStockerl-Goldstein2MichaelRetting3Sarah MLarson4ArpadIlles5GiuseppeMilone6MassimoMartino7PatrickStiff8Douglas WSborov9Denise LPereira10Ivana NMicallef11GemmaMoreno Jimnez12GborMikala13Maria LizPaciello Coronel14UdoHoltick15John WHiemenz16Muzaffar HQazilbash17Nancy MHardy18TahirLatif19IreneGarca-Cadenas20EllaSorani21LironShemesh-Darvish22AbiVainstein23ShaulKadosh22John FDiPersio1 (2021). Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. [Abstract]. 138(Supplement 1), 2849.
9. Zachary DCrees1Keith EStockerl-Goldstein2SarahLarson3rpdIlls4GiuseppeMilone5MassimoMartino6PatrickStiff7Douglas WSborov8Denise LPereira9Ivana NMicallef10GemmaMoreno Jimnez11GborMikala12Maria lizpaciello Coronel13UdoHoltick14John WHiemenz15Muzaffar HQazilbash16Nancy MHardy17TahirLatif18IreneGarca-Cadenas19AbiVainstein20EllaSorani21IritGliko-Kabir22InbalGoldstein22ShaulKadosh22John FDiPersio1 (2021). Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. [Abstract]. 138(Supplement 1), 475.
10. Victoria AVardell1Daniel AErmann2Srinivas KTantravahi3BrianMcClune4Mary NicoleSteinbach5Ghulam RehmanMohyuddin6AmandeepGodara6Douglas WSborov6 (2021). Multiple Myeloma Patients Treated  at Academic Centers Have Improved Survival Outcomes [Abstract]. 138(Supplement 1), 1971.
11. Rosalie G Waller, Heidi A Hanson, Michael J Madsen, Brian Avery, Douglas Sborov, Nicola J Camp (2020). Spectra: Agnostic Expression Variables for Flexible Transcriptome Modeling in Complex Disease [Abstract]. https://doi.org/10.1101/2020.10.06.20206714.
12. Rosalie G Waller, Heidi A Hanson, Michael J Madsen, Brian Avery, Douglas Sborov, Nicola J Camp (2020). Transcriptome Spectra: Agnostic Expression Variables to Empower Genomic Epidemiology Studies [Abstract]. https://doi.org/10.1101/2020.10.06.20206714.
13. Rosalie G Waller, Michael J Madsen, John Gardner, Douglas Sborov and Nicola J Camp (2020). Characterization of quantitative gene-expression dimensions in myeloma tumors [Abstract]. 10.1158/1538-7755.MODPOP19-A40.
14. Hans Chulhee Lee, Adam D Cohen, Ajai Chari, Malin Hultcrantz, Ajay K Nooka, Natalie Scott Callander, Attaya Suvannasankha, Ashraf Badros, Edward N Libby, Suzanne Trudel, Paul G Richardson, Douglas Weston Sborov, Paula Rodrguez Otero, Sagar Lonial, Eric Zhi, Eric Lewis, Ira Gupta, Joanna Opalinska (2020). DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment [Abstract]. 10.1200/JCO.2020.38.15_suppl.8519.
15. Douglas Weston Sborov, Domenico Viola, Ada A Dona, Ajay K Nooka, Jonathan L Kaufman, Sagar Lonial, Lawrence Boise, Madhav V Dhodapkar, Nisha Joseph, Flavia Pichiorri, Craig C Hofmeister (2020). Oncolytic virus pelareorep plus carfilzomib phase 1 trial in carfilzomib-refractory patients (NCI 9603): Responses with cytokine storm [Abstract]. 38(15), 1645-1750.
16. Sagar Lonial, Hans Chulhee Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola A Abdallah, Natalie Scott Callander, Douglas Weston Sborov, Attaya Suvannasankha, Katja Weisel, Peter Michael Voorhees, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Roxanne C Jewell, Joanna Opalinska, Ira Gupta, Adam D Cohen (2020). Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs) [Abstract]. 38(15).
17. Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, Phelps MA, Hofmeister CC, Poi MJ (2019). XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. [Abstract].
18. Peter M Voorhees, MD, Jonathan L Kaufman, MD, Jacob P Laubach, MD, Douglas W Sborov, MD MSc, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, MD, Rebecca W Silbermann, MD, Luciano J Costa, MD PhD, Larry D Anderson, MD PhD, Nitya Nathwani, MD, Nina D Shah, MD, Yvonne A Efebera, MD MPH, Caitlin L Costello, MD, Andrzej Jakubowiak, MD PhD, Tanya M Wildes, MD, Robert Z Orlowski, MD PhD, Kenneth H Shain, MD PhD, Andrew J Cowan, MD, Sean Murphy, Yana Lutska, PharmD, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Carla de Boer, Daniela Hoehn, MD PhD, Thomas S Lin, MD PhD, Paul G Richardson, MD (2019). Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) improves over time in patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM):Griffin Study Update [Abstract]. 653 Myeloma: Therapy Excluding Transplantation.
19. Ada Dona, PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y Krishnan, MD, Matt Coffey, PhD, Douglas W Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD (2019). Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma [Abstract]. 652.Myeloma:Pathophysiology and Pre-Clinical Studies, Excluding Therapy.
20. Peter Voorhees Jonathan L Kaufman Jacob Laubach Douglas Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano Costa Larry Anderson Nitya Nathwani Nina Shah Yvonne Efebera Caitlin Costello Andrzej Jakubowiak Tanya Wildes Robert Z Orlowski Kenneth H Shain Andrew Cowan Sean Murphy Yana Lutska Huiling Pei Jon Ukropec Jessica Vermeulen Carla de Boer Daniela Hoehn Thomas Lin Paul G Richardson (2019). Daratumumab+lenalidomide, bortezomib & dexamethasone improves depth of response in transplant-eligible newly diagnosed multiple myeloma: GRIFFIN [Abstract]. 19(10).
21. Saad Usmani Chatchada Karanes William I Bensinger Anita DSouza Noopur Raje Sascha Tuchman Douglas Sborov Dheepak Kanagavel Franck Dubin Frank Campana Paul G Richardson (2019). Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study [Abstract]. 19(10).
22. Jacken Waters Reuben Benjamin Stella Bowcock Kirsty Cuthill Sophie Deppe Ana Duran Maestre Douglas Gunning Maj Kazmi Alice Mason Grace Milner Hannah Patrick Carmel Rice Matthew Streetly (2019). Comparing clinical trial data against a real world dataset - progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment [Abstract]. 19(10).
23. Craig C Hofmeister, Douglas W Sborov, Domenico Viola, Ada Dona, Gelard J Nuovo, Don M Benson Jr, Sagar Lonial, Jonathan L Kaufman, Ajay K Nooka, Leonard Heffner, Madhav V Dhodapkar, and Flavia Pichiorri (1/1/19). Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patient Increases PD-L1 Expression with Clinical Responses [Abstract].
24. Nidhi Sharma, Nita Williams, Ashley E Rosko, Don M Benson Jr, Maria Chaudhry, Craig C Hofmeister, Douglas W Sborov, and Yvone Efebera (1/1/19). Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up [Abstract]. Blood.
25. MING J POI123, JUNAN LI14, JASMINE A JOHNSON1, YU KYOUNG CHO3, DOUGLAS W SBOROV5, MITCH A PHELPS34 and CRAIG C HOFMEISTER6 (2018). A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients [Abstract].
26. Greg D Whitehill, BS12, Alicia Chivers, MS1, Bryan Danielson, PhD1, Julien SR Tessier, MS1, Gabriela Hernandez Duran1, Gabrielle L Bender, BS1, Douglas W Sborov, MD, MSc3, Craig C Hofmeister, MD4, James Bradner, MD5, Teru Hideshima, MD, PhD6, Kenneth C Anderson, MD6 and Gullu Gorgun, PhD7 (12/11/17). Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment [Abstract].
27. Sabarinath Venniyil Radhakrishnan, MBBS, MD1, Tim Luetkens, MD1, Sara Yousef, PhD1, Neelam Bhardwaj, PhD1, Mary Nicole Steinbach, NP1, Janet Weidner1, Christa Shorter, BSc1, Douglas W Sborov, MD, MSc1 and Djordje Atanackovic, MD2 (12/10/17). Chimeric Antigen Receptor (CAR) T Cells Specific for CD229: A Potentially Curative Approach for Multiple Myeloma [Abstract].
28. Tim Luetkens, MD1, Sara Yousef, PhD1, Christa Shorter, BSc1, Srinivas K Tantravahi, MBBS1, Mary Nicole Steinbach, NP1, Janet Weidner1, Douglas W Sborov, MD, MSc1 and Djordje Atanackovic, MD2 (12/9/17). In Vivo Vaccination Effect in Clinical Responders to Anti-Myeloma Monoclonal Antibody Isatuximab [Abstract].
29. Cottini F, Sborov DW, Cho YK, Lamprecht M, Tackett K, Li J, Devine SM, Poi M, Phelps MA, Hofmeister CC (2016). G-CSF starting day +1 after autologous transplant is safer than day +5 or day +7 in patients with multiple myeloma [Abstract]. ASH Abstract. 128:5790.
30. Bhatt G, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski SM, Devine SM, Wildes TM, Jones D, Huang Y, Rosko AE (2016). A feasibility study of electronic geriatric assesment for real-time morbidity evaluation. [Abstract]. ASCO Annual Meeting Proceedings, 34(15).
31. Snoad B, Hudzik S, Sborov DW, Williams N, Jones D, Hofmeister CC (2015). The Majority of Myeloma Patients Are Hypogonadal but this is not Associated with High Risk Cytogenetics; also presented as a poster at the 57th American Society of Hematology Annual Meeting, 5-8 December 2015, Orlando, FL [Abstract]. Blood, 126(23).
32. Sborov DW, Pichiorri F, Nuovo JG, Benson DM, Efebera YA, Rosko AE, Hofmeister CC (2015). Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients; also presented as a poster at the 57th American Society of Hematology Annual Meeting, 5-8 December 2015, Orlando, FL [Abstract]. Blood, 126(23).
33. Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine SM, Wildes T, Gillahan JE, Huang Y, Burd CE (2015). Geriatric Assessment Metrics are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients; also presented as a poster at the 57th American Society of Hematology Annual Meeting, 5-8 December 2015, Orlando, FL [Abstract]. Blood, 126(23).
34. Hudzik S, Snoad B, Mousa L, Sborov DW, Williams N, Jones D, Hofmeister CC (2015). The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics [Abstract]. Blood, 126(23).
35. Cho YK, Li J, Wang J, Gao Y, Sborov DW, Lamprecht M, Jukich M, Falk W, Schaaf LJ, Poi M, Hofmeister CC, Phelps MA (2015). Pharmacokinetic and Pharmacodynamic Modeling for Personalizing Melphalan Dosing in Multiple Myeloma Patients Receiving Autologous Transplant [Abstract].
36. Sborov DW, Pichiorri F, Nuovo JG, Benson DM, Efebera YA, Rosko AE, Hofmeister CC (2015). Combination Carfilzomib and the Viral Oncolytic Agent Reolysin in Patients with Relapsed Multiple Myeloma: a Pilot Study Investigating Viral Proliferation; also presented as a poster at the 15th International Myeloma Workshop [Abstract]. Clinical Lymphoma Myeloma and Leukemia, 15(Suppl 3), e301.
37. Rosko AE, Jofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine S, Wildes TM, Gillahan J, Jones D, Huang Y (2015). Geriatric assessment metrics are associated with hospital length of stay in pre-bone marrow transplant myeloma patients [Abstract]. Blood, 126(23), 3200.
38. Sborov DW, Lamprecht M, Benson DM, Tackett K, Efebera YA, Rosko AE, Devine SM, Poi M, Phelps M, Hofmeister CC (2014). 2-hour cryotherapy effectively reduces severe mucositis associated with high dose melphalan followed by stem cell rescue: results from a randomized trial; also presented as a poster at the 56th American Society of Hematology Annual Meeting, 6-9 December 2014, San Francisco, CA [Abstract]. Blood, 124(21), 3960.
39. Cho YK, Li J, Sborov DW, Wang J, Gao Y, Lamprecht M, Poi M, Phelps MA, Hofmeister CC (2014). Development of a predictive pharmacokinetic and pharmacodynamics model to personalize melphalan dosing in autologous transplant for patients with multiple myeloma; also presented as a poster at the 56th American Society of Hematology Annual Meeting, 6-9 December 2014, San Francisco, CA [Abstract]. Blood, 124(21), 1086.
40. Cordero H, Sborov DW, Canella A, Liu Z, Wang J, Radomska H, Stiff A, Cortrill J, Consiglio J, Ni W, Smith E, Efanov A, Rizzotto L, Benson DM, Cascione L, Mo X, Phelps MA, Chan KK, Byrd JC, Grever MR, Hofmeister CC, Pichiorri F (2014). HDAC inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide; also presented as a poster at the 56th American Society of Hematology Annual Meeting, 6-9 December 2014, San Francisco, CA [Abstract]. Blood, 124(21), 3377.
41. Sborov DW, Marsh L, Yearsley M, Geyer S, Falk W, Devine SM, Hofmeister CC (2014). Utility of CMV PCR in the Evaluation of Allograft Recipients Presenting with Diarrhea; also presented as a poster at the 2014 BMT Tandem Meetings, February 26 - March 2, 2014, Grapevine, TX [Abstract]. Biology of Blood and Marrow Transplantation, 20(Suppl 2), S250-1.
42. Sborov DW, Nuovo G, Stiff A, Mace T, Lesinski G, Benson DM, Efebera YA, Rosko A, Pichiorri F, Hofmeister CC (2013). A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma; also presented as a poster at the 55th American Society of Hematology Annual Meeting, 7-10 December 2013, New Orleans, LA [Abstract]. Blood, 122(21), 3208.
43. Stiff A, Badway J, Nuovo G, Sborov D, Smith E, Talabere T, Hofmeister C, Pichiorri F (2013). Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment; also presented as a poster at the 55th American Society of Hematology Annual Meeting, 7-10 December 2013, New Orleans, LA [Abstract]. Blood, 122(21), 3232.

Other

1. Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F (2023). Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget (14, pp. 837-838). United States. ()
2. Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diepstra A, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquires H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N (2023). Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. England. ()

Video/Film/CD/Web/Podcast

1. D Sborov (2023). Case Based Roundtable - Challenging Cases of Relapsed/Refractory Multiple Myeloma Co-Moderator - Dr. Douglas Sborov https://event.targetedonc.com/event/e75aef30-ef62-45c3-9f64-00cfb8129940/websitePage:f850481a-22fe-442f-9254-bd15d6d0a859 [Web]. Healthcare and Research Analytics.
2. D Sborov (2022). Becoming a Partner with Your Healthcare Team - Douglas Sborov - RT Salt Lake City UT, Health Tree Foundation [Web]. Available: https://www.youtube.com/watch?v=NVSW42iMIDM.
3. D Sborov (2022). Douglas Sborov Leads Faculty Discussion | RT Salt Lake City, UT - Health Tree Foundation [Web]. Health Tree Foundation. Available: https://www.youtube.com/watch?v=QW1Fk7rdJ3g.
4. D Sborov (2022).  Your Path to Empowerment Multiple Myeloma, Patient Empowerment Network [Video]. Patient empowerment network. Available: https://powerfulpatients.org/2022/03/15/path-to-empowerment-multiple-myeloma-testing/.
5. D Sborov (2022). The Impact of Multiple Myeloma on Family Life - Patient Power [Video]. Patient Power. Available: https://www.patientpower.info/multiple-myeloma/patient-stories/the-impact-of-multiple-myeloma-on-family-life.
6. D Sborov (2022). ASH 2021: Cellular Therapies in Myeloma. Yale Cancer Center Featuring Noffa Bar [Video]. Online: VuMedi. Available: https://www.vumedi.com/video/ash-2021-cellular-therapies-in-myeloma/.
7. D Sborov (2022). Path to Empowerment: Multiple Myeloma | Testing. Patient Empowerment Network [Video]. Online: Patient Empowerment Network. Available: https://powerfulpatients.org/2022/03/15/path-to-empowerment-multiple-myeloma-testing/.
8. D Sborov (2022). The Role of Trust in Managing High-Risk Multiple Myeloma - Our Multiple Myeloma: Greg's Story - Patient Power [Web]. Patient Power. Available: https://www.patientpower.info/multiple-myeloma/patient-stories/the-role-of-trust-in-managing-high-risk-multiple-myeloma.
9. D Sborov, M Steinbach (2022). How My Multiple Myeloma Journey Started - Our Multiple Myeloma - Greg's Story - Patient Power [Video]. online: Patient Power. Available: https://www.patientpower.info/multiple-myeloma/patient-stories/how-my-multiple-myeloma-journey-started.
10. D Sborov (2021). ASH 2021: Bispecific Antibodies for Multiple Myeloma - Patient Power [Video]. https://www.patientpower.info/multiple-myeloma/conference-coverage/ash-2021-bispecific-antibodies-for-multiple-myeloma: Patient Power.
11. D Sborov (2021).   Institutional Perspectives in Cancer- Multiple Myeloma: Chaired by Douglas Sborov, MD, MS, OncLive, IPC Series [Web]. OncLive. Available: https://www.onclive.com/view/institutional-perspectives-in-cancer--multiple-myeloma-chaired-by-douglas-sborov-md-ms.
12. D Sborov (2021). Dr. Sborov on the Toxicities Associated with Novel Therapies in Multiple Myeloma | OncLive [Web]. OncLive. Available: https://www.onclive.com/view/dr-sborov-on-the-toxicities-associated-with-novel-therapies-in-multiple-myeloma.
13. D Sborov (2021). Is Multiple Myeloma Hereditary? Janssen Oncology, Patient Power [Web]. Patient Power. Available: https://www.patientpower.info/multiple-myeloma/ask-the-expert/is-multiple-myeloma-hereditary.
14. D Sborov, M Steinbach (2021). Doctor and Nurse Practitioner Discuss Myeloma Treatment | Douglas W. Sborov, MD MS & Mary Steinbach APRN Nurse Practitioner, University of Utah/Huntsman Cancer Institute Division of Hematology & Hematologic Malignancies. - Patient Power Newsletter   [Web]. Patient Power. Available: https://www.patientpower.info/multiple-myeloma/doctor-and-nurse-practitioner-discuss-myeloma-treatment.
15. D Sborov (2021). Dr. Sborov on Managing Bispecific Antibody-Related Adverse Effects in Multiple Myeloma. OncLive [Video]. Online: OncLive. Available: https://www.onclive.com/view/dr-sborov-on-managing-bispecific-antibody-related-adverse-effects-in-multiple-myeloma.
16. D Sborov (2021). Dr. Sborov on Mitigating Monoclonal Antibody - Associated Toxicity in Multiple Myeloma - OncLive TV [Video]. Online: OncLive. Available: https://www.onclive.com/view/dr-sborov-on-mitigating-monoclonal-antibody-associated-toxicities-in-multiple-myeloma.
17. D Sborov (2021). Talks with Docs: Douglas Sborov, Multiple Myeloma Director at HCI [Web]. Online: Huntsman Cancer Institute. Available: https://www.docwirenews.com/urban-health-today/urban-health-multiple-myeloma-knowledge-hub/urban-health-multiple-myeloma-knowledge-hub-video/multiple-myeloma-care-during-the-pandemic-with-dr-sborov/.
18. D Sborov (2021). Dr. Sborov Discusses Expanding Access to MM Clinical Trials. DocuWire News [Video]. Online: Urban Health Today. Available: https://www.docwirenews.com/urban-health-today/urban-health-multiple-myeloma-knowledge-hub/urban-health-multiple-myeloma-knowledge-hub-video/dr-sborov-discusses-expanding-access-to-mm-clinical-trials/.
19. D Sborov (2021). Multiple Myeloma Care During the Pandemic, with Dr. Sborov [Web]. Online: Urban Health Today. Available: https://www.docwirenews.com/urban-health-today/urban-health-multiple-myeloma-knowledge-hub/urban-health-multiple-myeloma-knowledge-hub-video/multiple-myeloma-care-during-the-pandemic-with-dr-sborov/.
20. D Sborov (2021). Simple Diagnostic Tests Empowering Multiple Myeloma Patients; BBC Story Works, Connecting the Dots; Skyline-dx  [Web]. BBC. Available: https://www.bbc.com/storyworks/connecting-the-dots/skyline-dx.
21. D Sborov (2021). Douglas Sborov, MD, on Expanding Access to Multiple Myeloma Clinical Trials, DocWire News [Web]. DocWire. Available: https://www.youtube.com/watch?v=zxJeS9f5Fzo.
22. Sborov DW, Hofmeister CC (Jan 5, 2015). Multiple Myeloma Case Study: Refractory MM in high-risk patients: Efficacy with Proteosome Inhibitor Therapy [Web]. Projects in Knowledge, e-publication.
23. Sborov DW, Hofmeister CC (Jan 5, 2015). Multiple Myeloma Case Study: High Risk Relapsing MM: Efficacy with retreatment with Immunomodulatory Therapy [Web]. Projects in Knowledge, e-publication.
24. Sborov DW, Hofmeister CC (April 23, 2014). Multiple Myeloma Case Study: Refractory MM: Efficacy of Retreatment with Immunomodulatory Therapy [Web]. Projects in Knowledge, e-publication.
25. Sborov DW, Hofmeister CC (March 31, 2014). Multiple Myeloma Case Study: Relapsed MM: Efficacy of Retreatment with Immunomodulatory Therapy [Web]. Projects in Knowledge, e-publication.

Huntsman Cancer Institute News

• Talks with Docs: Douglas Sborov, Multiple Myeloma Director at HCI
• Why I Participate in Employee Giving
• Sticking with the Positive through Multiple Myeloma